top of page

September 28 | Daily COVID-19 LST Report


· Cardiologists and biostatisticians from Denmark conducted a cohort study of 4002 patients to identify severity outcomes between COVID-19 patients (n=688) who were prescribed ibuprofen (42; 15.9%) versus those who were not (646; 17.3%) in a 30-day composite endpoint. The study concluded that there were no significant associations or adverse effects between patients prescribed ibuprofen and COVID-19 severity (p=0.70). Due to several confounding factors, the authors suggest that more studies need to be performed to evaluate this association.

Transmission & Prevention

· Allergy and Immunology experts from México conducted a prospective observational trial of 255 individuals recently vaccinated with mumps, measles, and rubella (MMR) for symptoms of COVID-19 infection and found that 24 eventually tested positive for COVID-19, and 12 were designated as highly probable. Of these patients, all exhibited mild disease leading the authors to suggest that vaccination with a non-SARs-CoV-2 vaccine could potentially minimize the severity of COVID-19 infection.

· A literature review by hematology experts associated with the Australian Red Cross found that although there are no reported instances of transfusion transmission of SARS-CoV-2, there is still potential for transfusion transmission since the virus exists in the blood in low levels. The authors recommend mitigation protocols against the possible risk of COVID-19's transfusion transmissibility at donation centers, such as donor deferral policies based on travel, diseased status, or potential risk of exposure.

· Investigators of medicinal chemistry and nutrition review the antiviral and cytokine-inhibitory mechanisms of lauric acid, enhanced phagocytic activity in high medium-chain triglyceride (MCT) diets, and suppression of several pro-inflammatory cytokines with intermittent fasting. They propose a ketogenic diet with intermittent fasting and supplemental MCT as a potential SARS-CoV-2 prophylaxis or adjuvant therapy for those with infection.

R&D: Diagnosis & Treatments

· Infectious disease experts and immunologists examine the sensitivity and specificity of anti-SARS-CoV-2 antibody tests using five ELISAs, seven colloidal gold lateral flow immunoassays, and ten commercial serological assays on 110 serum samples collected from 87 individuals with known COVID-19 infections and found that tests varied from 60.9% to 87.3% in sensitivity and 82% to 100% in specificity, but it was clear that all tests achieved the highest performance on samples taken at or greater than 20 days after onset of symptoms.

Click here to download full report



Thanks for submitting!

bottom of page